Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab

(2012) Vafa Shahabi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Ipilimumab in advanced melanoma

(2012) Alberto Farolfi et al.   MELANOMA RESEARCH

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and clinical activity of ipilimumab in melanoma patients with brain metastases

(2011) Jeffrey S. Weber et al.   MELANOMA RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

(2011) C. Garbe et al.   ONCOLOGIST

Determinants of survival in patients with brain metastases from cutaneous melanoma

(2010) M Staudt et al.   BRITISH JOURNAL OF CANCER

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations

(2010) B. Comin-Anduix et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Prognostic Factors in Metastatic Melanoma Patients Treated with Biochemotherapy and Maintenance Immunotherapy

(2009) D. R. Minor et al.   ONCOLOGIST

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY